NCT01397084

To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 107 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.

Conditions

• Gastroesophageal Reflux Disease
• GERD
• Reflux Esophagitis

Interventions

Type	Name	Description
DRUG	esomeprazole 20 mg	esomeprazole 20 mg once daily for 8 weeks

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2011-07-19
• Last updated: 2013-02-21
• Results posted: 2013-02-18